巨亏26亿后,“疫苗之王”,开始赚钱了

侃见财经
07 Nov 2024

全文2401字,阅读约需7分钟,帮我划重点划重点01尽管疫苗行业仍面临价格战,但随着时间推移,价格战将无法持续,行业有望实现分化。02康泰生物和沃森生物等头部疫苗企业在研发和创新方面取得进展,业绩逐渐回暖。03然而,康希诺作为曾经的疫苗之王,仍面临较大的股价压力,年内跌幅超过26%。04随着新冠疫苗需求的持续释放,康希诺的业绩有望持续改善。以上内容由腾讯混元大模型生成,仅供参考尽管价格战还在继续,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10